Latest Articles
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com
Published: July 31, 2026, 2:37 p.m.
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce Pharma
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis Fierce Pharma
Published: July 31, 2026, 2 p.m.
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer - Endpoints News
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer Endpoints News
Published: July 31, 2026, 10:42 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - Medical Professionals Reference
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial Medical Professionals Reference
Published: July 31, 2026, 4 a.m.
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial - empr.com
Selinexor Misses Primary Endpoint in Endometrial Cancer Trial empr.com
Published: July 31, 2026, 4 a.m.
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer - Seeking Alpha
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer Seeking Alpha
Published: July 30, 2026, 11:38 p.m.
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study - FirstWord Pharma
Karyopharm slumps after Xpovio misses mark in Phase III endometrial cancer study FirstWord Pharma
Published: July 30, 2026, 9:59 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - TipRanks
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint TipRanks
Published: July 30, 2026, 9:16 p.m.
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint - tipranks.com
Karyopharm’s endometrial cancer candidate did not meet Phase 3 primary endpoint tipranks.com
Published: July 30, 2026, 9:16 p.m.
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com - Investing.com Nigeria
Karyopharm endometrial cancer trial misses primary endpoint By Investing.com Investing.com Nigeria
Published: July 30, 2026, 8:42 p.m.
Link copied to clipboard!